Moving successful virus-specific T-cell therapy for hematopoietic stem cell recipients to late phase clinical trials

Molecular Therapy Nucleic Acids

Volumn 1, Issue 11, 2012, Pages

  Rooney, Cliona ^a,b   Leen, Ann ^a,b  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ANTIGEN; VIRUS VECTOR;

ADENOVIRUS; ARTICLE; CELL EXPANSION; CELL THERAPY; CLINICAL TRIAL (TOPIC); CYTOMEGALOVIRUS; EPSTEIN BARR VIRUS; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA SYSTEM; HUMAN; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS INFECTION;

EID: 84869430607     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2012.49     Document Type: Article

References (28)

1. Kennedy-Nasser, AA, Bollard, CM, Myers, GD, Leung, KS, Gottschalk, S, Zhang, Y et al. (2008). Comparable outcome of alternative donor and matched sibling donor hematopoi-etic stem cell transplant for children with acute lymphoblastic leukemia in frst or second remission using alemtuzumab in a myeloablative conditioning regimen. Biol Blood Marrow Transplant 14: 1245-1252
2. Renaud, C and Campbell, AP (2011). Changing epidemiology of respiratory viral infections in hematopoietic cell transplant recipients and solid organ transplant recipients. Curr Opin Infect Dis 24: 333-343.
3. Schönberger, S, Meisel, R, Adams, O, Pufal, Y, Laws, HJ, Enczmann, J et al. (2010). Pro-spective, comprehensive, and effective viral monitoring in children undergoing allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 16: 1428-1435.
4. Leen, AM, Tripic, T and Rooney, CM (2010). Challenges of T cell therapies for virus-as-sociated diseases after hematopoietic stem cell transplantation. Expert Opin Biol Ther 10: 337-351
5. Walter, EA, Greenberg, PD, Gilbert, MJ, Finch, RJ, Watanabe, KS, Thomas, ED et al. (1995). Reconstitution of cellular immunity against cytomegalovirus in recipients of al-logeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333: 1038-1044.
6. Heslop, HE, Slobod, KS, Pule, MA, Hale, GA, Rousseau, A, Smith, CA et al. (2010). Long-term outcome of EBV-specifc T-cell infusions to prevent or treat EBV-related lymphoprolif-erative disease in transplant recipients. Blood 115: 925-935.
7. Leen, AM, Myers, GD, Sili, U, Huls, MH, Weiss, H, Leung, KS et al. (2006). Monoculture-derived T lymphocytes specifc for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 12: 1160-1166. (Pubitemid 44527351)
8. Rooney, CM, Smith, CA, Ng, CY, Loftin, S, Li, C, Krance, RA et al. (1995). Use of gene-modifed virus-specifc T lymphocytes to control Epstein-Barr-virus-related lymphoprolif-eration. Lancet 345: 9-13.
9. Rooney, CM, Smith, CA, Ng, CY, Loftin, SK, Sixbey, JW, Gan, Y et al. (1998). Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92: 1549-1555 (Pubitemid 28406858)
10. Berger, C, Jensen, MC, Lansdorp, PM, Gough, M, Elliott, C and Riddell, SR (2008). Adop-tive transfer of effector CD8+ T cells derived from central memory cells establishes persis-tent T cell memory in primates. J Clin Invest 118: 294-305.
11. Cobbold, M, Khan, N, Pourgheysari, B, Tauro, S, McDonald, D, Osman, H et al. (2005). Adoptive transfer of cytomegalovirus-specifc CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 202: 379-386. (Pubitemid 41126955)
12. Leen, AM, Christin, A, Khalil, M, Weiss, H, Gee, AP, Brenner, MK et al. (2008). Identifca-tion of hexon-specifc CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol 82: 546-554. (Pubitemid 350309169)
13. Leen, AM, Christin, A, Myers, GD, Liu, H, Cruz, CR, Hanley, PJ et al. (2009). Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood 114: 4283-4292.
14. Gerdemann, U, Christin, AS, Vera, JF, Ramos, CA, Fujita, Y, Liu, H et al. (2009). Nucleo-fection of DCs to generate Multivirus-specifc T cells for prevention or treatment of viral infections in the immunocompromised host. Mol Ther 17: 1616-1625.
15. Neudorfer, J, Schmidt, B, Huster, KM, Anderl, F, Schiemann, M, Holzapfel, G et al. (2007). Reversible HLA multimers (Streptamers) for the isolation of human cytotoxic T lymphocytes functionally active against tumor-and virus-derived antigens. J Immunol Methods 320: 119-131 (Pubitemid 46349106)
16. Rauser, G, Einsele, H, Sinzger, C, Wernet, D, Kuntz, G, Assenmacher, M et al. (2004). Rapid generation of combined CMV-specifc CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants. Blood 103: 3565-3572. (Pubitemid 38525695)
17. Schmitt, A, Tonn, T, Busch, DH, Grigoleit, GU, Einsele, H, Odendahl, M et al. (2011). Adop-tive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specifc CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation. Transfusion 51: 591-599.
18. Mackinnon, S, Thomson, K, Verfuerth, S, Peggs, K and Lowdell, M (2008). Adoptive cel-lular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specifc T cells. Blood Cells Mol Dis 40: 63-67. (Pubitemid 350192302)
19. Moosmann, A, Bigalke, I, Tischer, J, Schirrmann, L, Kasten, J, Tippmer, S et al. (2010). Ef-fective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood 115: 2960-2970.
20. Feuchtinger, T, Matthes-Martin, S, Richard, C, Lion, T, Fuhrer, M, Hamprecht, K et al. (2006). Safe adoptive transfer of virus-specifc T-cell immunity for the treatment of sys-temic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 134: 64-76. (Pubitemid 43830030)
21. Vera, JF, Brenner, LJ, Gerdemann, U, Ngo, MC, Sili, U, Liu, H et al. (2010). Accelerated production of antigen-specifc T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother 33: 305-315.
22. Gerdemann, U, Vera, JF, Rooney, CM and Leen, AM (2011). Generation of multivirus-specifc T cells to prevent/treat viral infections after allogeneic hematopoietic stem cell transplant. J Vis Exp: 2736.
23. Kern, F, Faulhaber, N, Frommel, CC, Khatamzas, E, Prösch, S, Schönemann, C et al. (2000). Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. Eur J Immunol 30: 1676-1682 (Pubitemid 30342810)
24. Haque, T, Taylor, C, Wilkie, GM, Murad, P, Amlot, PL, Beath, S et al. (2001). Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Ep-stein Barr virus-specifc cytotoxic T cells. Transplantation 72: 1399-1402. (Pubitemid 33015766)
25. Haque, T, Wilkie, GM, Jones, MM, Higgins, CD, Urquhart, G, Wingate, P et al. (2007). Al-logeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 110: 1123-1131. (Pubitemid 47281407)
26. Haque, T, McAulay, KA, Kelly, D and Crawford, DH (2010). Allogeneic T-cell therapy for Epstein-Barr virus-positive posttransplant lymphoproliferative disease: long-term follow-up. Transplantation 90: 93-94.
27. Barker, JN, Doubrovina, E, Sauter, C, Jaroscak, JJ, Perales, MA, Doubrovin, M et al. (2010). Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specifc cytotoxic T lymphocytes. Blood 116: 5045-5049.
28. Doubrovina, E, Ofaz-Sozmen, B, Prockop, SE, Kernan, NA, Abramson, S, Teruya-Feld-stein, J et al. (2012). Adoptive immunotherapy with unselected or EBV-specifc T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood 119: 2644-2656.